Search

The article is devoted to the study of determining key performance indicators of the marketing mix effectiveness in the pharmaceutical business. The problems and contradictions in ensuring the effectiveness of marketing in pharmaceutical companies are emphasized. Theoretical and applied foundations for implementing the marketing mix in the pharmaceutical business are highlighted. The expediency of following the «5Ps» and «6Ps» marketing mix is justified due to their correspondence to the specific features of marketing in the pharmaceutical business. Based on the research, a system of key performance indicators of the marketing mix effectiveness in the pharmaceutical business is identified.

Objectives. To establish details of catalytic systems operation using the kinetic method with no needs for the differentiation of primary experimental kinetic data.Methods. Analysis of the time patterns of differential selectivity and relative reactivity of substrates in parallel or competing reactions was used.Results. For various coupling reactions of aryl halides and nucleophiles, the possibility to obtain the data about the evolution of the catalytic systems and patterns of the changes of catalytically active species under dynamic transformations of several active and inactive catalyst forms was demonstrated.Conclusions. The analysis of the evolution of differential selectivity and relative reactivity under competing or parallel reactions is the useful tool for discrimination between probable hypotheses of complex catalytic process operation.

The results of efficacy and safety study of abatacept and methotrexate combination therapy (n=12) in comparison with methotrexate monotherapy (n =41) in patients with polyarticular juvenile idiopathic arthritis at the age of 4–17 years old are shown in this article. The duration of the observation was 1 year. Abatacept was introduced at a dose of 10 mg/kg at 1st, 2d and then — every 4th week. In 48 weeks clinical remission and decrease of laboratory markers of activity was registered in 35% of patients treated with abatacept and methotrexate and in 16% of patients treated only with methotrexate.

On the basis of a complex morphological study of human placenta the characteristic structural features of villous maldevelopment in a combination of edema of pregnant and anemia of pregnancy are defined by the type of dissociated cotyledon development with retardation of the placental barrier functional specialization. This pathology leads to compensatory reactions of the placenta in the form of the restructuring of fetal blood vessels, aimed only at the oncoming of fetal and maternal blood flow without increasing of the vasculosyncytial membranes area. These changes were accompanied by complicated delivery and fetus state disorder characteristic for chronic feto-placental insufficiency, 2-nd degree of severity. Received results are the basis for inclusion of pregnant women with early form of EPH-gestosis (edema of pregnant) in combination with anemia into the risk group of fetoplacental insufficiency developing and complicated delivery.

In this study the results of the investigation of complex treatment with Infliximab and Methotrexate efficacy and safety of 28 patientscomparing with Methotrexate treatment of 41 patients with polyarticular juvenile idiopathic arthritis at the age of 8–17 years are analyzed. The follow-up period was 1 year. Infliximab was administered according to the following scheme: 0, 2, 6 weeks and then every 8 weeks. The dosage of Infliximab in children with early onset of juvenile idiopathic arthritis was 3,0 mg/kg per infusion. Clinical remission, decrease and normalization of laboratory markers, complete restoration of joints function and improvement of life quality in 57,7% were established after 46 weeks of treatment with Infliximab and Methotrexate comparing with 16% in children treated with Methotrexate monotherapy.